Twist Bioscience Co. (NASDAQ:TWST) Insider Sells $10,983.96 in Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 234 shares of the business’s stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $46.94, for a total value of $10,983.96. Following the transaction, the insider now owns 78,393 shares of the company’s stock, valued at $3,679,767.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Dennis Cho also recently made the following trade(s):

• On Monday, August 5th, Dennis Cho sold 709 shares of Twist Bioscience stock. The shares were sold at an average price of $39.93, for a total value of $28,310.37.
• On Tuesday, July 2nd, Dennis Cho sold 126 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total transaction of $6,048.00.

Twist Bioscience Trading Up 3.1 %

NASDAQ:TWST opened at $47.08 on Friday. The company has a 50-day moving average price of $46.46 and a 200-day moving average price of $43.24. The stock has a market cap of $2.76 billion, a price-to-earnings ratio of -14.01 and a beta of 1.76. Twist Bioscience Co. has a 12 month low of $14.42 and a 12 month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The firm had revenue of $81.50 million for the quarter, compared to the consensus estimate of $77.40 million. During the same period in the previous year, the firm posted ($1.01) earnings per share. The business’s revenue was up 27.7% compared to the same quarter last year. Equities analysts forecast that Twist Bioscience Co. will post -3.13 EPS for the current fiscal year.

Hedge Funds Weigh In On Twist Bioscience

Institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its position in shares of Twist Bioscience by 34.8% in the 1st quarter. BNP Paribas Financial Markets now owns 171,823 shares of the company’s stock worth $5,895,000 after buying an additional 44,349 shares during the period. UBS Group AG increased its stake in shares of Twist Bioscience by 106.4% during the fourth quarter. UBS Group AG now owns 213,467 shares of the company’s stock valued at $7,868,000 after purchasing an additional 110,036 shares in the last quarter. SageView Advisory Group LLC purchased a new position in shares of Twist Bioscience during the first quarter valued at approximately $1,144,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Twist Bioscience in the 1st quarter worth approximately $300,000. Finally, Sei Investments Co. grew its stake in shares of Twist Bioscience by 32.7% in the 1st quarter. Sei Investments Co. now owns 223,555 shares of the company’s stock worth $7,670,000 after buying an additional 55,124 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on TWST shares. Barclays decreased their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. Robert W. Baird increased their target price on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. Guggenheim started coverage on Twist Bioscience in a research note on Tuesday, June 4th. They set a “buy” rating and a $53.00 price target for the company. The Goldman Sachs Group increased their price objective on Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, July 9th. Finally, TD Cowen increased their price target on shares of Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, June 13th. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $48.22.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.